Italia markets closed

Dow Jones
39.862,35
+304,24(+0,77%)
Nasdaq
16.744,26
+233,08(+1,41%)
Nikkei 225
38.385,73
+29,67(+0,08%)
EUR/USD
1,0884
+0,0062(+0,58%)
Bitcoin EUR
60.358,57
+3.851,42(+6,82%)
CMC Crypto 200
1.382,73
+114,78(+9,05%)

NVCR Jan 2025 17.500 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

7,68

+1,68

(+28,00%)

In data: 12:04PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in